Cargando…

PD-1 Inhibitors Plus Capecitabine as Maintenance Therapy for Advanced Intrahepatic Cholangiocarcinoma: A Case Report and Review of Literature

Intrahepatic cholangiocarcinoma (iCCA) is the second most common primary liver cancer with a poor prognosis. Recently, an immunotherapy strategy represented by programmed cell death 1 (PD-1) inhibitors has been applied to the systemic treatment of advanced iCCA. However, immunotherapy combined with...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Zhihong, Zeng, Tianmei, Li, Yong, Zhang, Ding, Yuan, Zhengang, Huang, Mengli, Yang, Yuan, Zhou, Weiping
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8739978/
https://www.ncbi.nlm.nih.gov/pubmed/35003124
http://dx.doi.org/10.3389/fimmu.2021.799822
_version_ 1784629216978927616
author Wang, Zhihong
Zeng, Tianmei
Li, Yong
Zhang, Ding
Yuan, Zhengang
Huang, Mengli
Yang, Yuan
Zhou, Weiping
author_facet Wang, Zhihong
Zeng, Tianmei
Li, Yong
Zhang, Ding
Yuan, Zhengang
Huang, Mengli
Yang, Yuan
Zhou, Weiping
author_sort Wang, Zhihong
collection PubMed
description Intrahepatic cholangiocarcinoma (iCCA) is the second most common primary liver cancer with a poor prognosis. Recently, an immunotherapy strategy represented by programmed cell death 1 (PD-1) inhibitors has been applied to the systemic treatment of advanced iCCA. However, immunotherapy combined with chemotherapy as first-line maintenance therapy was rarely reported. Our report presented an advanced iCCA patient who had a dramatic response to the PD-1 inhibitor sintilimab combined with gemcitabine plus cisplatin as the first-line therapy and sintilimab combined with capecitabine as maintenance therapy, yielding an ongoing progression-free survival of 16 months.
format Online
Article
Text
id pubmed-8739978
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-87399782022-01-08 PD-1 Inhibitors Plus Capecitabine as Maintenance Therapy for Advanced Intrahepatic Cholangiocarcinoma: A Case Report and Review of Literature Wang, Zhihong Zeng, Tianmei Li, Yong Zhang, Ding Yuan, Zhengang Huang, Mengli Yang, Yuan Zhou, Weiping Front Immunol Immunology Intrahepatic cholangiocarcinoma (iCCA) is the second most common primary liver cancer with a poor prognosis. Recently, an immunotherapy strategy represented by programmed cell death 1 (PD-1) inhibitors has been applied to the systemic treatment of advanced iCCA. However, immunotherapy combined with chemotherapy as first-line maintenance therapy was rarely reported. Our report presented an advanced iCCA patient who had a dramatic response to the PD-1 inhibitor sintilimab combined with gemcitabine plus cisplatin as the first-line therapy and sintilimab combined with capecitabine as maintenance therapy, yielding an ongoing progression-free survival of 16 months. Frontiers Media S.A. 2021-12-24 /pmc/articles/PMC8739978/ /pubmed/35003124 http://dx.doi.org/10.3389/fimmu.2021.799822 Text en Copyright © 2021 Wang, Zeng, Li, Zhang, Yuan, Huang, Yang and Zhou https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Wang, Zhihong
Zeng, Tianmei
Li, Yong
Zhang, Ding
Yuan, Zhengang
Huang, Mengli
Yang, Yuan
Zhou, Weiping
PD-1 Inhibitors Plus Capecitabine as Maintenance Therapy for Advanced Intrahepatic Cholangiocarcinoma: A Case Report and Review of Literature
title PD-1 Inhibitors Plus Capecitabine as Maintenance Therapy for Advanced Intrahepatic Cholangiocarcinoma: A Case Report and Review of Literature
title_full PD-1 Inhibitors Plus Capecitabine as Maintenance Therapy for Advanced Intrahepatic Cholangiocarcinoma: A Case Report and Review of Literature
title_fullStr PD-1 Inhibitors Plus Capecitabine as Maintenance Therapy for Advanced Intrahepatic Cholangiocarcinoma: A Case Report and Review of Literature
title_full_unstemmed PD-1 Inhibitors Plus Capecitabine as Maintenance Therapy for Advanced Intrahepatic Cholangiocarcinoma: A Case Report and Review of Literature
title_short PD-1 Inhibitors Plus Capecitabine as Maintenance Therapy for Advanced Intrahepatic Cholangiocarcinoma: A Case Report and Review of Literature
title_sort pd-1 inhibitors plus capecitabine as maintenance therapy for advanced intrahepatic cholangiocarcinoma: a case report and review of literature
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8739978/
https://www.ncbi.nlm.nih.gov/pubmed/35003124
http://dx.doi.org/10.3389/fimmu.2021.799822
work_keys_str_mv AT wangzhihong pd1inhibitorspluscapecitabineasmaintenancetherapyforadvancedintrahepaticcholangiocarcinomaacasereportandreviewofliterature
AT zengtianmei pd1inhibitorspluscapecitabineasmaintenancetherapyforadvancedintrahepaticcholangiocarcinomaacasereportandreviewofliterature
AT liyong pd1inhibitorspluscapecitabineasmaintenancetherapyforadvancedintrahepaticcholangiocarcinomaacasereportandreviewofliterature
AT zhangding pd1inhibitorspluscapecitabineasmaintenancetherapyforadvancedintrahepaticcholangiocarcinomaacasereportandreviewofliterature
AT yuanzhengang pd1inhibitorspluscapecitabineasmaintenancetherapyforadvancedintrahepaticcholangiocarcinomaacasereportandreviewofliterature
AT huangmengli pd1inhibitorspluscapecitabineasmaintenancetherapyforadvancedintrahepaticcholangiocarcinomaacasereportandreviewofliterature
AT yangyuan pd1inhibitorspluscapecitabineasmaintenancetherapyforadvancedintrahepaticcholangiocarcinomaacasereportandreviewofliterature
AT zhouweiping pd1inhibitorspluscapecitabineasmaintenancetherapyforadvancedintrahepaticcholangiocarcinomaacasereportandreviewofliterature